HMGB1 and Sepsis: A prior study has demonstrated that recombinant HMGB1 mediated cytosolic translocation of LPS and induced caspase-11–dependent immune responses in sepsis and has uncovered that HMGB1 could be a potential pharmacological target for treating sepsis (Deng et al., 2018).